Biocon jumps 7% on ₹3,481-crore Mylan exit deal

What drove Biocon’s sharp move on Tuesday

Biocon shares rose sharply in early trade after large block deals were executed in the counter, triggering renewed focus on the company’s shareholding changes. The stock surged 7.13% to ₹440.25 after the block deal activity, according to the trading update. Separately, it was reported to be up about 6% to ₹434 on the NSE during Tuesday’s intra-day deals following the transaction. By 09:32 AM, Biocon was quoted 5.4% higher at ₹433.35, while the Nifty 50 was down 0.38% at the time. The move put the stock close to its 52-week high of ₹440.40, which was last touched on May 26, 2026.

Block deal execution details from exchange data

NSE data showed 45.98 million equity shares, representing 2.82% of Biocon’s total equity, changed hands via a block deal in the pre-open session. The deal size was reported at ₹1,839.34 crore and was executed at an average price of ₹400 per share. On the BSE, as many as 46.54 million equity shares changed hands during the block transactions. The volumes and the timing, in the pre-open session, typically indicate a pre-arranged large trade between institutions. The reported average execution price also helped market participants infer the likely pricing band relative to the previous day’s close.

Mylan named as likely seller, with a full exit in focus

Multiple reports indicated U.S.-based Viatris-owned Mylan was looking to sell its entire holding in Biocon through block deals. The planned sale was pegged at around 5.6% to 5.64% of Biocon’s equity, with the overall stake value estimated at about ₹3,481 crore. If completed as described, the transaction would mark Mylan’s complete exit from Biocon after a 17-year partnership. Moneycontrol, citing industry sources, said the trade was intended to be a “clean out” transaction after the lock-in period lapsed. The same reports described the holding as a non-core investment for Mylan, with the seller looking to unlock value through a full exit.

Offer terms: floor price and discount to Monday’s close

The block deal was reported to have been launched at a floor price of ₹378.50 per share. Reports pegged this as a 7.8% to 7.9% discount to Biocon’s Monday closing price on the NSE, reflecting the typical pricing mechanism used to place large secondary sales. While the floor price sets the lower bound for the transaction, the actual execution in the pre-open session was reported at an average of ₹400 per share for the portion that traded. The difference between the floor price and the average execution is important for assessing how much demand was available at the time of the trade.

How big was Mylan’s stake in Biocon

As on June 29, 2026, Mylan Inc held 91.96 million equity shares in Biocon, representing a 5.64% stake, according to shareholding pattern data cited in reports. Reuters also reported that Mylan, as part of Viatris, planned to sell up to 5.64% stake in Biocon worth up to ₹3,481 crore. With 2.82% of equity reported to have traded via a block deal on the NSE in the pre-open session, investors tracked whether additional tranches would follow to complete the full exit. The stated intention across reports was a complete sale of Mylan’s holding.

Link to Biocon Biologics integration and the Viatris settlement

The stake sale comes after a series of corporate actions around Biocon Biologics and Viatris. Reports said Mylan acquired its stake after Biocon completed an acquisition involving the company’s holding in Biocon Biologics in January 2026 through a combination of a share swap and cash consideration, which included a preferential allotment of Biocon shares. Separately, Biocon had announced it would fully integrate Biocon Biologics into the parent company, valuing the biosimilar business at about $1.5 billion. Under the Viatris agreement, Biocon would acquire Viatris’s residual stake for a total consideration of $115 million, consisting of $100 million in cash and $115 million in newly issued equity shares of Biocon.

Funding and balance sheet metrics cited in earlier disclosures

To fund the cash component payable to Viatris, Biocon’s board approved raising additional capital of up to ₹4,500 crore through a qualified institutional placement, along with bridge loans, as reported. In the same set of disclosures and interviews, executive chairperson Kiran Mazumdar-Shaw said the merger structure was designed to remove the holding company discount and strengthen financial metrics. The debt-to-EBITDA ratio was cited as improving from 4.3x in 2020 to 2.5x “today,” with expectations of further deleveraging mentioned in the interview excerpts. The company also said it had retired structural equity debt from Kotak and Goldman Sachs and others, which would free up about ₹300 crore of provisioning interest.

What the market watched beyond the block deal headline

The immediate market reaction on Tuesday centred on the block deal supply and whether the seller was exiting fully at one go or in multiple tranches. Investors also tracked price behaviour relative to the 52-week high of ₹440.40, given the stock was trading close to that level in early deals. Another factor in the background has been investor sensitivity to equity issuance and ownership changes linked to the Biocon Biologics integration and the planned fundraise. Separately, Biocon had earlier reported that its net profit was ₹84.50 crore in the second quarter of FY26, compared with a net loss of ₹16 crore in the same period a year earlier, according to financial reports cited.

Key facts at a glance

Why the transaction matters for Biocon’s ownership narrative

A full exit by Mylan would close a long-running shareholding association that was described as a 17-year partnership. It also arrives at a time when Biocon has been restructuring around Biocon Biologics, including the $115 million transaction with Viatris and the plan to integrate the biosimilars business valued at about $1.5 billion. With block deals, the key market question typically becomes the identity and profile of the incoming buyers, since that can influence near-term liquidity and longer-term shareholding stability. The reports also frame the planned transaction as a clean exit after the lock-in lapsed, which suggests the trade is tied to transaction mechanics rather than a change in Biocon’s operating outlook.

What to watch next

The market will watch for additional block deal disclosures if further tranches are executed to complete the reported full stake sale. Investors will also track updates tied to the broader Biocon Biologics integration timeline, which was expected to be completed by March 31, 2026, and the funding actions linked to the cash component payable under the Viatris agreement. Any exchange filings around bulk or block deals, and subsequent changes in shareholding patterns, will clarify how much of the reported 5.64% stake has changed hands and to whom.